Behçet's Disease

vetswidow Sleepysheepy jasmin 83782 353 Users are discussing this topic

PatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

See also: Behçet's Disease written for patients

Synonym: Behçet's syndrome

Behçet's disease is a complex multi-system disorder of unknown aetiology characteristically presenting with recurrent oral ulcers. It is presumed to be an autoimmune disease and includes involvement of the mucocutaneous, ocular, cardiovascular, renal, gastrointestinal, pulmonary, vascular, musculoskeletal, urological and central nervous systems.  In many patients the activity of this disease diminishes with time.

  • This condition is not commonly seen in Northern Europeans.The prevalence is highest in the Middle East, Mediterranean and Eastern Asia.[1]
  • It is most common among patients aged 20-30 years.
  • An age of onset younger than 25 years is associated with a higher prevalence of eye disease and active clinical disease.
  • Males and females are equally affected.
  • However, males tend to have a more active and more severe form of the disease.
  • Behçet's disease is associated with HLA-B51.
  • There is a genetic predisposition.  
  • It is possibly an autoimmune condition although it is not actually associated with the presence of auto-antibodies.
    • Nonspecific symptoms include tiredness, malaise, muscle pains, and transient fevers.
    • Headaches can be common.
    • Although oral ulceration, genital ulceration and eye disease are the classic triad of manifestations, the cardiovascular, gastrointestinal, musculoskeletal and central nervous systems can also be affected.[2] . 
    • Skin and mucous membranes:
    • Painful aphthous ulcers occur in any part of the moist mucosal surfaces inside the mouth. They do not occur actually on the lips. The ulcers may last for as long as three weeks.
    • Skin lesions can occur in the genital regions. The ulcers are very painful.  They do not usually occur on the penis.
    • Painful nodules on the legs can occur due to erythema nodosum.
    • Patients often present with acne-like lesions on the arms and/or legs.
  • Around 50% of patients have uveitis. Other ocular manifestations include hypopyon, retinal vasculitis, retinal haemorrhage, blurred vision and photophobia.
  • Neurological: central nervous system (CNS) involvement occurs late in the disease. Memory impairment is the most common CNS manifestation. Impairment of balance, speech and movement can also occur. Thrombosis within the dural venous sinuses may occur. Peripheral nerve involvement is rare.[3]
  • Cardiovascular:
  • Arthritis: arthritis and arthralgias are common; a non-erosive arthritis occurs which most often affects the lower limbs, especially the knee. It can also affect the small joints. Back pain due to sacroiliitis may also occur.
  • Gastrointestinal: cramping abdominal pain, vomiting, diarrhoea or, less commonly, gastrointestinal bleeding can occur. Ulcerative lesions may occur in any part of the gastrointestinal tract.
  • Other manifestations include epididymitis, glomerulonephritis, lymphadenopathy, myositis, and polychondritis. Amyloidosis may occur but is very uncommon.

NEW - log your activity

  • Notes
    Add notes to any clinical page and create a reflective diary
  • Track
    Automatically track and log every page you have viewed
  • Print
    Print and export a summary to use in your appraisal
Click to find out more »

The International Study Group criteria are currently used to define the illness:[4]

The patient has recurrent oral ulcers and two of the following manifestations in the absence of other systemic diseases:

  • Recurrent genital aphthous ulceration or scarring observed by a physician or reported reliably by the patient.
  • Skin lesions (including erythema nodosum-like lesions, pseudofolliculitis, papulopustular lesions, or acneiform nodules) observed by a physician in a post-adolescent patient not receiving corticosteroids.
  • Eye involvement with anterior/posterior uveitis or retinitis observed by an ophthalmologist.
  • Positive pathergy test performed with oblique insertion of a ≤21-gauge needle under sterile conditions and interpreted by a physician at 48 hours.
  • This depends on which systems are involved.
  • Differential diagnosis of oral or genital ulcers includes herpes simplex, hand, foot and mouth disease, herpangina, histoplasmosis, inflammatory bowel disease, seronegative spondyloarthropathies, acne vulgaris, rheumatoid arthritis.

Investigations are not required to confirm the diagnosis. However, they can help to rule out a differential diagnosis.

  • FBC may show mild anaemia and raised white cell count.
  • Nonspecific inflammatory markers: CRP, ESR, complement and acute-phase reactants may all be elevated during an acute attack.
  • Antiphospholipid antibodies are positive in 25% of patients.
  • Pathergy test: minor skin trauma induces an inflammatory papule or pustule after 24-48 hours. This is positive in up to 60% of patients.
  • Imaging studies, including CT and/or MRI scan, may be undertaken in some patients.
  • Angiography is required to identify and assess aneurysms.
  • Patients positive for HLA-B51 or HLA-B5 are more likely to be male and also have a higher prevalences of genital ulcers, ocular and skin manifestations, and a decreased prevalence of gastrointestinal involvement.[5]

The aim of treatment is to prevent long-term damage. The most severe manifestation present in the patient usually determines the choice of treatment.

  • Local therapy:
    • Topical corticosteroids (eg, triamcinolone paste) are effective for oral or genital ulcerations if they are applied during the prodromal stage of ulceration when the symptoms are more mild.
  • Systemic manifestations:
    • Lesions resistant to local measures may require systemic treatment.
    • Systemic treatments are usually given for 1-2 years. They may be given longer for those with gastrointestinal involvement.
    • Patients with eye involvement need early and more aggressive treatment, usually with a brief course of corticosteroid with a longer-term immunosuppressant (eg, azathioprine).[1]
    • Patients with CNS involvement require the most aggressive treatment, usually with a corticosteroid plus either azathioprine, cyclophosphamide, or a TNF-alpha inhibitor.
    • Continual use of immunosuppressive medications may be required to suppress disease.
    • Corticosteroids are effective for acute manifestations but there is no evidence of any beneficial effect on disease progression.
    • TNF antagonists - eg, infliximab - can be effective.
  • Mucocutaneous lesions and joint involvement:[7]
    • These may respond to non-steroidal anti-inflammatory drugs, prednisolone, levamisole, colchicine, dapsone, or sulfapyridine and thalidomide.
    • In most patients, arthritis can be managed with colchicine. Local corticosteroid injections may also be used.
    • Immunosuppressive therapy with azathioprine may be effective.
  • Major vessel disease:
    • Vasculitis is treated with immunosuppressive medication.
    • Prevention of acute deep vein thrombosis is by using immunosuppressive agents rather than anticoagulants.
    • However, if a venous thrombotic event does occur then warfarin is usually given.
    • For pulmonary and peripheral arterial aneurysms, immunosuppressants and corticosteroids are usually given.


This may be required for:

  • Gastrointestinal complications - eg, perforation and peritonitis.
  • Aneurysms or ischaemic tissues affected by vasculitis or thrombosis.
  • Ventricular aneurysms and coronary thrombosis.
  • Eye involvement - eg, glaucoma, cataracts or retinal detachment.
  • CNS aneurysms or clots.
  • Vasculitis, rupture of aneurysms and thrombosis may all lead to potentially fatal cardiovascular complications.
  • CNS involvement can lead to permanent deficits.
  • Eye involvement may result in blindness.
  • There is a very variable course of recurrences and remissions lasting for years.
  • The majority of new manifestations occur within the first five years after onset of the disease.
  • Prognosis will depend on which systems are involved. Men tend to have a poorer prognosis.[8]
  • Mortality is usually low but death may occur as a result of neurological involvement, vascular disease, bowel perforation, cardiopulmonary disease, or as a complication of immunosuppressive therapy.
  • Many patients go into remission with time.
  • Although treatment of skin-mucosal manifestations, eye disease and pulmonary artery aneurysms has improved significantly in the past couple of decades, the treatment of CNS lesions is still problematic[9] .

Further reading & references

  1. Fresko I, Yazici H; Treatment strategies for Behcet's disease. Expert Opin Pharmacother. 2008 Dec;9(18):3211-9.
  2. Ambrose NL, Haskard DO; Differential diagnosis and management of Behcet syndrome. Nat Rev Rheumatol. 2012 Sep 25. doi: 10.1038/nrrheum.2012.156.
  3. Al-Araji A, Kidd DP; Neuro-Behcet's disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009 Feb;8(2):192-204.
  4. No authors listed; Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet. 1990 May 5;335(8697):1078
  5. Maldini C, Lavalley MP, Cheminant M, et al; Relationships of HLA-B51 or B5 genotype with Behcet's disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford). 2012 May;51(5):887-900. Epub 2012 Jan 11.
  6. EULAR recommendations for the management of Behçet disease; European League Against Rheumatism (January 2008)
  7. Yousefi M et al; Dermatologic Aspects of Behcet Disease, Medscape, Jul 2012
  8. Yazici H, Esen F; Mortality in Behcet's syndrome. Clin Exp Rheumatol. 2008 Sep-Oct;26(5 Suppl 51):S138-40.
  9. Yazici H, Fresko I, Yurdakul S; Behcet's syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol. 2007 Mar;3(3):148-55.

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.

Original Author:
Dr Colin Tidy
Current Version:
Peer Reviewer:
Dr Hayley Willacy
Document ID:
1852 (v22)
Last Checked:
Next Review:

Did you find this health information useful?

Yes No

Thank you for your feedback!

Subcribe to the Patient newsletter for monthly healthcare and news updates.

We would love to hear your feedback!

Patient Access app - find out more Patient facebook page - Like our page